biopharmaceuticals

Atossa Therapeutics Inc (NASDAQ: ATOS) shares are trading higher Tuesday after retail traders were able to push the stock higher. The stock was trading on above-average volume Tuesday and was trending on social media sites throughout the day such as StockTwits. Atossa Therapeutics was up 13.42...

ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmic yutoantibody associated vasculitis. The U.S. Food and Drug Administration (FDA) filing was...

Nkarta Inc. (NASDAQ: NKTX) announced on Tuesday the underwriters for its initial public offering have completely exercised their overallotment option to purchase 2.1 million additional shares. This brings the biopharmaceutical company's total amount raised in the IPO to $289.8 million. It...

Three stocks that had been digesting recent gains now appear to be on the rise again. ArQule, Inc. (NASDAQ: ARQL) gained 42 cents to $7.17 on 2.6 million shares Tuesday. The move, on more than 1/2 times its average volume, came on no news from the biopharmaceutical company. The stock broke out of a...

Research-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) announced Monday it has named Daniel O'Day as its chairman of the board and CEO, effective March 1. What Happened O'Day joins Gilead after more than three decades of experience at Roche Holdings AG Basel ADR (OTC...

Biopharma Omeros Corporation (NASDAQ: OMER) released additional data Monday from the company’s OMS721 clinical trial in renal disease.  What Happened Omeros shares were down 42.81 percent at $13.96 at the close monday.  The Phase 2 trial measured protein levels in the...

NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK) and Incyte Corporation (NASDAQ: INCY) said their clinical trial of the similar drug epacadostat...

Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...

Genocea Biosciences Inc (NASDAQ: GNCA) announced a 40-percent workforce reduction Monday as it officially shifts focus to immuno-oncology and neoantigen cancer vaccines and explores strategic alternatives for its former lead candidate. The Street reacted with a sharp pullback and a Tuesday ratings...

Featured stories this weekend in Barron's ponder the prospects for a leading biopharmaceutical company, a manufacturer of automotive paints and a little-known insurance holding company. This issue also offers thoughts on economic reform from an outgoing CEO of a multinational industrial products...

Geoff Meacham of Barclays initiated coverage of six names within the "newly combined" U.S. Biopharmaceuticals sector. Meacham noted he is "positive" on the fundamentals and the "pipeline-driven evolution into a more specialty therapeutic areas." However, the...

Inotek Pharmaceuticals Corp (NASDAQ: ITEK), founded in 1999, is a clinical-stage biopharmaceutical company centered on the discovery, development and commercialization of therapies to treat glaucoma. Glaucoma is condition where the eye is unable to properly drain fluid, which leads to a buildup...

Companies producing so-called “plantibodies,” or plant-produced antibodies created by genetic engineering, have been attracting headlines recently. San Diego-based Mapp Pharmaceutical, which was acquired last year by Allergan (NYSE: AGN), has gotten global attention over the...